Although the genetic analysis of common disease has met with relatively little success to date, there is a growing sense that the tools necessary to deliver clinically relevant progress are slowly becoming available. In this meeting we sought to pull together many of the different strands of research that are relevant to understanding how human genetic variation influences both disease predisposition and response to treatment. The meeting was purposefully broad, reflecting our belief that progress will depend on inter-disciplinary approaches that combine an appreciation of the relevant clinical context, advanced genomic methodologies, and appropriate statistical and bioinformatics analyses. Given the potentially far reaching implications genetics will eventually have for human health, it is important to include social scientists, politicians, lawyers and the representatives of public health services as well as drug regulatory bodies into these discussions from the outset. Due to the severe constraints on some of the participants' time some speakers were not able to contribute a manuscript to this issue. We believe, however, that the breadth of the meeting can still be seen from the articles in this issue.
The article by Willard et al. (2005) serves as a broad overview over many of the central questions underlying genetic variation and its impact on human health. Willard has been instrumental in setting up a research centre which tries to cover all aspects of health-related genomics to the extent that 'policy' has made it into the name of his centre, the Institute for Genome Sciences & Policy. In their contribution the authors outline possible strategies for integrating different types of data-an area of concern and importance in all branches of the modern life sciences-and, after discussing some very promising but early results from the field of cancer genetics, move on to discuss future challenges. And challenges there will be many over the next few years: genomic medicine is going to be expensive. Social as well as scientific problems need to be overcome and the resulting debate will need to draw in people from very different backgrounds.
The paper by Kere (2005) outlines what can be done with present experimental methods. For some diseases the community is getting better at discovering the regions which may contain genes involved in the disease. Positional cloning has become a standard technique for locating such regions. But the community has, despite some early optimism, not been as successful at finding the 'true causal gene'. Kere shows how a combination of human genetic studies coupled with functional studies in the mouse model can be employed to locate and confirm causal loci. The interplay between population genetic measures (notably linkage disequilibrium) and basic biochemical processes underlying the disease enable but also limit the ability of pure genetic analyses. Kere, and many will agree with him there, ends by stressing the importance of understanding the function of genes, whether on their own or in concert with other genes, for the future of genomic medicine.
A further Scandinavian success story comes from Ingelman-Sundberg & Rodriguez-Antona (2005) who discuss a study of drug metabolizing enzymes. The burgeoning area of pharmacogenomics may contain many of the 'low-hanging fruit' in the wider field of health-related genomics, as the underlying genetic causes may turn out to be 'simpler' than for the complex diseases such as asthma, different cancers and neurological disorders. They discuss in some detail the role of cytochrome P450 and what is known about its role in pharmacogenomics. The authors show clearly the health benefits likely to result from better understanding of the genetic basis of drug metabolism. For this to succeed, however, they believe that science alone cannot deliver these benefits without the involvement of society and regulatory bodies.
The paper by Wood and co-authors (Gandhi et al. 2005) proposes a strategy for evaluating the role of candidate genes in complex diseases. They discuss this in the context of Parkinson's disease as an example for a neurological disorder which can appear in Mendelian, i.e. monogenetic, and complex forms. Their approach relies on starting from a set of genes known to be involved in causing Mendelian Parkinson's disease. For these genes a set of haplotype-tagging single nucleotide polymorphisms (SNPs) is identified, which are then used in a case-control design using a large number of patients with sporadic forms of Parkinson's disease. The authors discuss the approach, including their haplotype tagging strategy, its likely success and statistical caveats in detail in their contribution.
The case for why the genetic study of variable drug response is likely to be successful sooner than the study of complex diseases is further elaborated on by Goldstein (2005) . Crucially perhaps we now have a list of obvious-and often well studied-candidate genes involved in drug metabolism, and genetic variants underlying variable drug response phenotypes are often common with many or most of them having a minor allele frequency greater than 10% in at least some populations. This means that they are more likely to be detected by means of linkage disequilibrium. This combined with extensive functional data means that detecting and verifying causal genetic variants is more immediately promising in pharmacogenomics than in disease studies. The importance of pharmacogenomics is then discussed from a more applied drug development perspective by McCarthy et al. (2005) . This community is acutely aware of the benefits of genetic and functional studies in the design of novel drugs and in ensuring that the drug does what it is supposed to do. Often this will involve limiting the patient basis and we will see many more drugs coming onto the market which will be limited to certain groups which have a suitable genetic makeup. Middleton and his colleagues outline how pharmacogenetics and pharmacogenomics are currently being used during the drug development, evaluation processes. They also discuss that these techniques are still relevant once a drug is on the market: pharmacogenetics and pharmacogenomics can be used to monitor the efficacy and safety of the drug once it has reached a broad patient base. The paper by Lawrence et al. (2005) then begins a series of papers which focus on conceptual and statistical issues surrounding the genetic studies into human health and disease. Cardon and his co-authors (Lawrence et al. 2005) discuss why genetic association studies may be more difficult than many had hoped only a few years ago. Partially because of the increased resolution afforded by present population genetic data, with SNPs every few hundred base pairs in some cases, there has been a re-evaluation of the structure of linkage disequilibrium in humans. This, of course, determines the extent to which unknown genetic variants can be picked up from marker data in a casecontrol study. They discuss a range of potential problems for association studies, in particular for whole genome association studies. They illustrate their discussion using an example where they combined the results of recently published gene expression data with the preliminary HapMap data for that very same sample.
De Iorio et al. (2005) discuss an example of how recent developments in statistical methodology are likely to impact on population genetics. As all the other presentations have shown, understanding the genetic basis of disease and/or drug metabolism is made difficult by a variety of factors. Traditionally population genetics has employed simple models to interpret genetic data. Increasingly the community is extending and improving these models in order to find a framework that (i) allows us to analyse the data, but (ii) is also computationally feasible. The fact that genetic processes such as mutation and recombination do not occur uniformly along the DNA sequence has led to a flurry of activity aimed at describing and interpreting this variation. The authors present a novel approach at doing just this aimed at detecting hotspots of recombination. Understanding patterns of recombination rate variation allows us to understand linkage disequilibrium much better and may help to assess the likely benefit to be gained from association studies. Reich & Patterson (2005) discuss the extent to which recent mixing of different ethnic groups-each with its subtly different genetic makeup-can be used to identify regions which contain genes that may be involved in complex diseases. They present a study conducted in an African American population which has African as well as European ancestry. They briefly discuss their resource before evaluating the case for admixture mapping, an intellectually very appealing way of looking at genetic data; the true usefulness of it remains to be proven, though. Their balanced account suggests a set of a priori criteria which have to be met before admixture mapping can be declared a useful and powerful approach for discovering causal genes. Kraft & Hunter (2005) continue along this theme but also return to earlier strands of the discussion in their paper on how genetic association is to be integrated with epidemiology. The effects of many genetic variants are subtle and often hard to detect. Their main message is that performing statistically sound association studies will be much harder than many people had hoped only some years ago. Sample sizes will be large and studies will have to be planned very carefully. Moreover with genetic effects often being weak, inferences subject to considerable uncertainty and medical treatments being either non-existent or too expensive, the authors urge caution about the widespread application of potential genetic tests for complex disease variants.
Central to many manuscripts in this issue was a call for greater involvement of society and regulatory bodies. Unfortunately Baroness Kennedy and Professor Genn were unable to contribute manuscripts to this issue for they highlighted their concerns about the future uses of genomic methods and, especially, information from a legal and ethical perspective. In several of the papers outlined above the authors do, however, touch upon social, political and economical dimensions to this problem. And Shah (2005) , in the final paper of this issue, provides a comprehensive and lucid analysis of how regulatory bodies accommodate the wealth of genomic information becoming available. He believes that pharmacogenetics and genomics hold great promise for the future and will be widely employed in deciding which drug is allowed to enter the market and with what restrictions. We must not, however, underestimate the difficulties in gathering and interpreting such data and the fact that genes are not solely responsible in determining efficacy and safety of a drug. Their effects are modulated by a multitude of different factors, including lifestyle choices and the potential presence of other drugs.
On balance, the articles in this issue put roughly equal weight on the potentials and problems facing the study of genetic variation related to human health and disease. It is important to keep in mind both, but at the end of the meeting we were left with a real sense of optimism that the field may be on the edge of more meaningful progress, and we hope this optimism comes across in the printed form.
